Qiagen
While low FGFR biomarker testing rates may be contributing to the drug's slow adoption, the analysis found low uptake even among patients who did get tested.
Qiagen Gets CE Mark for Therascreen EGFR Plus RGQ Kit for Non-Small Cell Lung Cancer
The firm has launched the in vitro diagnostic test, which detects EGFR mutations in non-small cell lung cancer, in 11 countries that accept the CE mark.
Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test for Investigational Lymphoma Treatment
The test will identify patients expressing a genomic biomarker who are likely to respond to Denovo's investigational DB102 treatment for diffuse large B-cell lymphoma.
Qiagen, OncXerna Therapeutics Ink Companion Dx Development, Technology-Licensing Deal
The partners will develop an NGS companion diagnostic for navicixizumab, which OncXerna is developing as a treatment for patients with ovarian cancer.
Qiagen, Sysmex Form Global Companion Diagnostic Development Pact
The companies will develop and commercialize liquid biopsy CDx assays using Sysmex's Plasma-Safe-SeqS next-generation sequencing technology.